Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Spontaneous Urticaria: full-pipeline trial registry
9 of 19 indexed Chronic Spontaneous Urticaria trials are currently recruiting.
Corpus placement: #902 of 28,707 conditions by registered trial count.
19 US clinical trials · 9 currently recruiting · #902 of 28,707 conditions by registered trial count
Chronic Spontaneous Urticaria: 19 US clinical trials tracked, 9 recruiting.
Chronic Spontaneous Urticaria is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 8 of these trials.
Enrollment posture brief
Registry condition chronic-spontaneous-urticaria
OPEN 9 | RECR 47% | LATE 8 | EARLY 6 | RANK #902 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Breast Cancer Stage I (47% recruiting · 19 trials)
Chronic Spontaneous Urticaria lists 9 open slots (47% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Spontaneous Urticaria on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Spontaneous Urticaria recruits in line with its size-band peers.
9 of 19 indexed trials (47.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Chronic Spontaneous Urticaria research.
Novartis Pharmaceuticals accounts for 8 of 19 trials (42.1%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Chronic Spontaneous Urticaria enrolment sits around 350 participants.
Median target enrolment is 350 among the 19 trials that report a genuine target (sentinel values excluded). 3 of those (15.8%) plan for fewer than 100 participants.
-
Chronic Spontaneous Urticaria research is mostly interventional.
14 interventional and 5 observational studies make up this index (73.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
19 total, page 1 of 1
Remibrutinib in Real-world Clinical Practice
Novartis Pharmaceuticals
NCT07358364
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
Celldex Therapeutics
NCT07256392
Remibrutinib in Real-world Clinical Practice - a US Sub-study
Novartis Pharmaceuticals
NCT07358780
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
Sanofi
NCT07316114
A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients
Novartis Pharmaceuticals
NCT07408219
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Pfizer
NCT07219615
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
Evommune
NCT06873516
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
Blueprint Medicines Corporation
NCT06931405
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Novartis Pharmaceuticals
NCT05677451
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Target PharmaSolutions
NCT03661866
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
Celldex Therapeutics
NCT06455202
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
Celldex Therapeutics
NCT06445023
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
Novartis Pharmaceuticals
NCT05513001
Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)
Jasper Therapeutics
NCT06162728
A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
Novartis Pharmaceuticals
NCT03580356
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU
Novartis Pharmaceuticals
NCT04109313
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
Novartis Pharmaceuticals
NCT05795153
Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001
Allakos
NCT06577116
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)
Sanofi
NCT05526521
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
| Phase 3 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Spontaneous Urticaria records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Spontaneous Urticaria trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Spontaneous Urticaria page
19 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Chronic Spontaneous Urticaria trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novartis Pharmaceuticals sponsors the most Chronic Spontaneous Urticaria trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Spontaneous Urticaria condition card totals 19 registered trials; most-linked intervention barzolvolimab; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.